So far, the best pharmacological tools to attenuate cognitive impairment in patients with mild-to-moderate Alzheimer’s disease (AD) are acetylcholinesterase inhibitors (AChEIs) [3,4,5]. The gene discussed is ACHE; the disease is Alzheimer disease.